Clinical trials: Hepatic Malignancies
Hepatic Impairment
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
The main purpose of this study is to evaluate the effect of varying degrees of impaired hepatic function (by Child Pugh classification) on the plasma PK of siremadlin after a single oral dose.
- Trial name
- NCT05599932
- Testing
- Siremadlin
- Where
- 3 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Liver Metastases
CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer
This is an open label, fixed dose, phase Ib trial of anti-CEA CAR-T cell infusions delivered via the hepatic artery or splenic vein using the Surefire Infusion System (SIS) for patients with CEA-expressing liver metastases or…
- Trial name
- HITM-SURE (NCT02850536)
- Testing
- anti-CEA CAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Roger Williams Medical Center
Colorectal Cancer
A Patient Portal Tool, E-assist, for Supporting CRC Screening
To compare patient perceptions, intent to screen, and screening use among those using a patient portal with and without a colorectal cancer (CRC) screening decision support tool, e-assist.
- Trial name
- NCT02798224
- Testing
- e-assist: Colon Health, Healthwise Educational Program
- Where
- United States
- Volunteers
- 1,826 people, healthy volunteers welcome
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Liver Stiffness And Steatosis Assessment In Women With Polycystic Ovary Syndrome Using Fibroscan
Polycystic Ovary Syndrome (PCOS) is a complex endocrine and metabolic disorder prevalent among women of reproductive age. It is closely associated with insulin resistance, obesity, and metabolic dysfunction, often leading to…
- Trial name
- NCT07027332
- Testing
- FibroScan® (Echosens, Paris, France)
- Where
- Turkey (Türkiye)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Hepatocellular Carcinoma
Neoadjuvant Radiotherapy for HCC Involving Type I PVTT
The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially those with type I or II PVTT.
- Trial name
- NCT04025437
- Testing
- Hepatectomy alone, Neoadjuvant radiotherapy
- Where
- China
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Hepatic Impairment (Mild and Moderate, Child-Pugh Class A and B), Hepatic Insufficiency (MeSH ID: D048550)
Pharmacokinetics and Safety of MDR-001 in Mild and Moderate Hepatic Impairment
This is a Phase I, single-center, open-label, parallel-group study. A single oral dose of MDR-001, a GLP-1 receptor agonist, will be administered to participants with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic…
- Trial name
- NCT07550634
- Testing
- MDR-001
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- MindRank AI Ltd
Hepatic Impairment, Healthy Volunteers
A Study to Evaluate ASP0367 in Participants With Mild/Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
The purpose of this study is to evaluate the effect of ASP0367 in participants with mild and moderate hepatic impairment compared to healthy participants with normal hepatic function.
- Trial name
- NCT04942964
- Testing
- Bocidelpar
- Where
- 3 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Lung Cancer, Squamous Cell Carcinoma
An Exploratory, Open Label, Multi-Center, Non-Randomized Study of [F-18]VM4-037
Phase: Exploratory Study Objectives: To collect drug bio-distribution data, begin collection of baseline and tumor/background imaging data, acquire experience to improve study design and the conduct of future studies Design…
- Conditions
- Lung Cancer, Squamous Cell Carcinoma, Head and Neck Cancer, Hepatic Carcinoma
- Trial name
- VM4-037 (NCT00884520)
- Testing
- [F-18] VM4-037
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Siemens Molecular Imaging
End Stage Liver Disease, Rejection
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients
To search for suitable pharmacodynamic biomarkers, i.e., with high specificity for calcineurin inhibition and most affected by inter-individual variability, our works aimed at exploring the pharmacodynamics of CNI, the strength…
- Conditions
- End Stage Liver Disease, Rejection, Infection, Malignancy
- Trial name
- 3PIGREF (NCT01760356)
- Where
- Uruguay
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- UDA Centro Nacional Hepato-Bilio-Pancreático
Chronic Liver Disease, Hepatic Carcinoma
A Study to Evaluate Vaccines Against COVID-19 in the Real World
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (COVID-19) have afflicted tens of millions of people in a worldwide pandemic.
- Trial name
- NCT04775056
- Where
- Hong Kong
- Volunteers
- healthy volunteers welcome
- Sponsor
- Humanity & Health Medical Group Limited
Pediatric Liver Transplanted Recipients, Healthy Donors
Living Donor Liver Transplantation in Children
Evaluate the outcome of pediatric living donor liver transplantation (LDLT) regarding portal vein reconstruction, ABO-compatibility and impact of maternal donation on graft acceptance.
- Trial name
- NCT02124382
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Colorectal Cancer, Liver Metastasis
Surgical Recovery After Left Lateral Hepatic Sectionectomy: Laparoscopic Versus Open Surgery.
The ORANGE II trial is a double blinded randomised controlled trial that will provide evidence on the merits of laparoscopic surgery in patients undergoing a left lateral hepatic sectionectomy in terms of time to functional…
- Conditions
- Colorectal Cancer, Liver Metastasis, Liver Disease
- Trial name
- ORANGE II (NCT00874224)
- Testing
- laparoscopic left lateral hepatic sectionectomy, open left lateral hepatic sectionectomy
- Where
- Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Hemangioma
Fluctuational Imaging for the Diagnosis of Hepatic Hemangioma: A Multicenter, Prospective Study
[Background and Rationale] Hepatic hemangioma is the most common benign tumor of the liver, with a reported prevalence of up to 20% in the general population.
- Trial name
- NCT07418294
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Breast Cancer, Leukemia, Myeloid, Chronic
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
The purpose of this study is to assess the pharmacokinetics of bosutinib and the safety and tolerability of bosutinib in healthy subjects and subjects with liver disease.
- Trial name
- NCT00759837
- Testing
- Bosutinib
- Where
- Poland
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Caregiver, Malignant Neoplasm
Patient Portal and Navigation Program in Providing Information for Asian American Cancer Patients
This phase I/II trial studies how well patient portal and navigation program work in providing information for Asian American cancer patients.
- Conditions
- Caregiver, Malignant Neoplasm, Physician, Stage I Colorectal Cancer AJCC v8
- Trial name
- NCT03867916
- Testing
- Patient Navigation Program, Quality-of-Life Assessment, Survey Administration
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Pancreas Neoplasm, Neuroendocrine Tumors
Portal Vein Resection in Pancreatic Neuroendocrine Tumours
The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific…
- Trial name
- PVNET (NCT04336839)
- Testing
- Portal vein resection / reconstruction
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Free Hospital NHS Foundation Trust
Mild and Moderate Hepatic Impairment
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
An Open-label, Single-center, Parallel-group Study to Assess Pharmacokinetics, Safety, and Tolerability of a Single Dose of MT-7117 in Subjects with Normal and Impaired Hepatic Function
- Trial name
- NCT04116476
- Testing
- MT-7117
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Hepatic Impairment
A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function
This is a Phase 1, multi-center, open-label, non-randomized, parallel group study to evaluate the effect of severe hepatic impairment on the PK, safety and tolerability of a single oral dose of Elacestrant.
- Trial name
- NCT06126575
- Testing
- Elacestrant dihydrochloride
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Stemline Therapeutics, Inc.
Hepatic Impairment
A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693
Subcutaneous administration of AZD2693 single dose in participants with hepatic impairment
- Trial name
- NCT05919069
- Testing
- AZD2693
- Where
- 3 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Participants, Gastrointestinal Neoplasms
A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib
This study evaluates the pharmacokinetics (PK), safety, and tolerability of velzatinib in participants with mild, moderate, and severe hepatic impairment (HI) and participants with normal hepatic function.
- Trial name
- NCT07859735
- Testing
- Velzatinib
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline